In regards to news this month on the Mash mice, there’s a very real possibility that they chose not to release it yet due to ongoing discussions related to why they pulled the abstract right after approval. The same reason they might have pulled the abstract (a partner getting serious who doesn’t want others seeing results and/or an opportunity to slip into their negotiations and put their plans at risk) is the same reason they may have those January estimated results and haven’t shared them. Not only are these other two trials similar to the first, but they’re actually even more important as they can help us expand our inflammation efforts and also tie us to GLP-1 drugs, which happen to be the hottest ticket in town.

So while I’d love to hear about the results, I anticipate hearing about a Mash partner before we do the Mash mice. I don’t think we’ll have to wait too long, to be honest.

#Strategery